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Case Report
Balloon atrial septostomy as initial therapy in pediatric
pulmonary hypertension
Paul J. Critser1, Patrick D. Evers2, Eimear McGovern3, Michelle Cash1 and Russel Hirsch1,4
1Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 2Division of Pediatric Cardiology, Oregon Health and Science University,
Portland, OR, USA; 3Division of Pediatric Cardiology, University of Kentucky College of Medicine, Lexington, KY, USA; 4Department of Pediatrics, University of
Cincinnati College of Medicine, Cincinnati, OH, USA
Abstract
Balloon atrial septostomy is a palliative procedure currently used to bridge medically refractory pulmonary hypertension patients
to lung transplantation. In the current report, we present balloon atrial septostomy as an initial therapy for high-risk pediatric
pulmonary hypertension patients at our institution. Nineteen patients with median age of 4.3 years (range 0.1–14.3 years)
underwent balloon atrial septostomy during initial admission for pulmonary hypertension. There were no procedural complications
or deaths within 24 h of balloon atrial septostomy. Patients were followed for a median of 2.6 years (interquartile range 1.0–4.8
years). Three (16%) patients died, 3 (16%) underwent lung transplantation, and 1 (5%) underwent reverse Potts shunt. Transplant-
free survival at 30 days, 1 year, and 3 years was 84%, 76%, and 67% respectively. This single-center experience suggests early-BAS in
addition to pharmacotherapy is safe and warrants consideration in high-risk pediatric pulmonary hypertension patients.
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Introduction
Survival of pediatric pulmonary hypertension (PH) patients
has improved over the last two decades due to new thera-
peutic agents. However, pediatric PH remains a progressive
disease with poor prognosis. For patients who fail to
respond to medical therapy, current guidelines recommend
balloon atrial septostomy (BAS) or reverse Potts shunt as a
bridge to lung transplantation.1
By providing an atrial level shunt, BAS may improve left
ventricular preload and cardiac output at the expense of
decreased systemic saturation. BAS has been associated
with improved survival in adult patients with PH.2 Two
reports have described BAS in pediatric PH, demonstrating
an association with symptomatic improvement.3,4 However,
the appropriate timing of BAS remains unclear as severe
right ventricular (RV) failure or end stage disease are rela-
tive contraindications.1
In the current report, we present our institutional experience
with BAS as an initial therapy for high-risk pediatric PH.
Cases
Between 1 January 2011 and 31 December 2019, BAS was
performed during initial admission for PH in 19 patients.
Eleven patients (52%) were female. The median age at pro-
cedure was 4.3 years (range 0.1–14.3 years). Eleven patients
(58%) had idiopathic pulmonary arterial hypertension,
5 (26%) had PH associated with congenital heart disease,
2 (10%) had PH after bone marrow transplant, and 1 (5%)
had hereditary hemorrhagic telangiectasia. Indications for
BAS included history of syncope, PH crisis, or evidence of
RV failure.
Preceding the BAS, 18 (95%) patients were admitted to
an intensive care unit, 13 (68%) patients were on inotropes,
and 6 (32%) patients were treated with inhaled nitric oxide.
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Eleven (58%) patients received pulmonary vasodilator ther-
apy with 5 (26%) receiving monotherapy, 4 (21%) receiving
dual therapy, and 2 (11%) receiving triple therapy. Eleven
(58%) patients received phosphodiesterase-5 inhibitors, 4
(21%) patients received an endothelin receptor antagonist,
and 4 (21%) patients received prostanoid therapy. Five
(24%) had history of syncope, 3 (16%) had experienced a
PH crisis, and 11 (58%) had echocardiographic evidence of
RV failure.
Fifteen patients underwent BAS at the time of initial car-
diac catheterization. The remaining four patients underwent
BAS at two, four, six, and eight days after initial cardiac
catheterization. At the time of BAS, the median cardiac
index was 3.1 L/min/m2 (interquartile range (IQR) 2.5–
4.3), mean pulmonary artery pressure was 58mmHg (IQR
49–72), pulmonary vascular resistance was 16.9 iWU (IQR
10.4–22.5), mean right atrial pressure (mRAP) was 8mmHg
(IQR 6–13), mean systemic arterial oxygen saturation 96%
(IQR 95–96). There were no procedural complications or
deaths within 24 h of BAS. Eleven patients received antic-
oagulation after BAS including aspirin in five, enoxaparin in
one, clopidogrel in one, and warfarin in five patients.
Patients were followed for a median of 2.6 years (IQR
1.0–4.8 years). Three patients required a repeat BAS. At
most recent follow-up, 14 (74%) had patent atrial level
shunt. Of the five patients with intact atrial septum, two
had atrial septal defect closure at time of lung transplant,
and three had spontaneous closure at 9, 10, and 15 months
after BAS.
Three (16%) patients died, 3 (16%) underwent lung
transplantation, and 1 (5%) underwent reverse Potts
shunt. The three patient deaths were within 30 days of the
procedure and were admitted to the intensive care unit prior
to BAS. One patient died from sepsis and two patients died
from a PH crisis. There were no deaths in patients who
survived to hospital discharge after BAS.
Three (16%) patients underwent lung transplantation at
7 months, 1 year, and 2 years after BAS and all are alive
with post-transplant follow-up of 3.5, 4, and 4 years.
Transplant-free survival at 30 days, 1 year, and 3 years
was 84%, 76%, and 67% respectively (Fig. 1).
Of the 13 patients with transplant-free survival, at most
recent follow-up, 3 (23%) were on no pulmonary vasodila-
tor therapy, 3 (23%) on monotherapy, 4 (30%) on dual
therapy, and 3 (23) on triple therapy. Ten (77%) patients
were treated with phosphodiesterase-5 inhibitors, 7 (54%)
with an endothelin receptor antagonist, and 5 (38%) with
prostanoid therapy.
Discussion
Current pediatric practice guidelines advocate the use of
BAS as a deferred therapy, reserved for those with severe
disease—characterized by RV failure, PH crises, functional
class decline, or syncope—refractory to medical therapy.1,5,6
There have been two recent descriptions of this
deferred-BAS strategy in pediatrics PH, both of which illus-
trate improved hemodynamics, functional outcomes, and
low procedural risk in cohorts of significantly ill children.3,4
However, there is a conceptual benefit of earlier BAS in
the care of these children, as opposed to those with medic-
ally refractory disease. The era prior to the advent of
modern pharmacotherapy provides insight into the hemo-
dynamic and clinical impact of atrial communications,
absent the confounding effects of concurrent pulmonary
vasodilators in the modern experience. An initially observed
survival advantage in adults with idiopathic PAH who had a
patent foramen ovale led to several septostomy trials in
adults with severe disease illustrating improvements in
symptoms, cardiac output, right atrial pressure, oxygen
delivery, and survival.7–10 More recently, Sandoval et al.
provided a description of the hemodynamic improvements
in 34 adult PH patients who were naı̈ve to pulmonary vaso-
dilator therapy.2 In this study, early-BAS led to improve-
ments in hemodynamic parameters correlated with survival
after septostomy as well as further improved survival
amongst those receiving early-BAS and subsequent pharma-
cotherapy over those receiving early-BAS alone.
In the enclosed single-center case-series, the outcomes of
an early-BAS approach in pediatrics are described. This
series demonstrates the safety of early-BAS in pediatrics:
we illustrate no procedural complications nor deaths
within 24 h of the procedure. Across the follow-up period,
our absolute survival and transplant-free survival are com-
parable to the previously reported modern experience from
other centers (Fig. 1). These outcomes are despite several
patients meeting criteria for relative contraindications for
BAS.1,10 Three (16%) had a mRAP> 20mmHg, the highest
being 33mmHg falling to 13mmHg after BAS. Four (21%)
patients had RV cardiac output 2.5Lminm2 with the
lowest being 0.85Lminm2. The only death from a PH
crisis was in a patient who met both criteria, 10 days follow-
ing BAS. While this complex and high-risk population
demands individualized care, this single-center experience
Fig. 1. Kaplan–Meier survival characteristics illustrating cohort’s
overall survival and transplant-free survival.
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supports consideration of early-BAS in addition to initiation
of aggressive pharmacotherapy in patients with high-risk
characteristics.
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